Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. - Wikidata - awgldk - TriplyDB

Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases.

Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases.

http://www.wikidata.org/entity/Q37412463

about

Longitudinal study of a human drug-induced model of autoantibody to cytoplasmic rods/rings following HCV therapy with ribavirin and interferon-α Evaluation of antinuclear antibodies by indirect immunofluorescence and line immunoassay methods': four years' data from Turkey.Prevalence of systemic autoimmune rheumatic diseases and clinical significance of ANA profile: data from a tertiary hospital in Shanghai, China.High prevalence of autoantibodies to RNA helicase A in Mexican patients with systemic lupus erythematosus.Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara.Autoantibodies to survival of motor neuron complex in patients with polymyositis: immunoprecipitation of D, E, F, and G proteins without other components of small nuclear ribonucleoproteins.Anti-PM/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma.Atypical clinical presentation of a subset of patients with anti-RNA polymerase III--non-scleroderma cases associated with dominant RNA polymerase I reactivity and nucleolar staining.Autoantibodies to transcription intermediary factor TIF1β associated with dermatomyositis.A new immunoprecipitation-real time quantitative PCR assay for anti-Th/To and anti-U3RNP antibody detection in systemic sclerosis.Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network.Autoantibodies in senear-usher syndrome: cross-reactivity or multiple autoimmunity?Coexistence of anti-RNA polymerase III and anti-U1RNP antibodies in patients with systemic lupus erythematosus: two cases without features of scleroderma.Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies.Inappropriate use of commercial Antinuclear Antibody Testing in a community-based US hospital: a retrospective study.Autoantibodies other than Anti-desmogleins in Pemphigus Vulgaris Patients.Laboratory evaluation in rheumatic diseases.Diagnostic Approaches to Sjögren's syndrome: a Literature Review and Own Clinical Experience.A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy.Myositis-specific autoantibodies: an important tool to support diagnosis of myositis.Prdm1 Regulates Thymic Epithelial Function To Prevent Autoimmunity.Autoimmune comorbidity in achalasia patients.Personalized medicine in rheumatology: the paradigm of serum autoantibodies.Rpp25 is a major target of autoantibodies to the Th/To complex as measured by a novel chemiluminescent assay.Complexes of DNA with fluorescent dyes are effective reagents for detection of autoimmune antibodies.What autoantibody tests should become widely available to help scleroderma diagnosis and management?Antinuclear antibody status and risk of death in children and adolescents.Undifferentiated connective tissue diseases and adverse pregnancy outcomes. An undervalued association?The Role of Hydroxychloroquine as a Steroid-sparing Agent in the Treatment of Immune Thrombocytopenia: A Review of the Literature.Potential Chronotherapeutic Optimization of Antimalarials in Systemic Lupus Erythematosus: Is Toll-Like Receptor 9 Expression Dependent on the Circadian Cycle in Humans?Anti-argonaute2 (Ago2/Su) and -Ro antibodies identified by immunoprecipitation in primary anti-phospholipid syndrome (PAPS)

P2860

Q28483978-60CBF1E6-F08A-44A6-878F-4C29B0F9C2FF Q30801548-469C35F6-E30D-4307-9C0E-8C4614FF95A3 Q31109622-10D02F94-1EFD-4CC3-BFDE-8A27E871D9A7 Q33523155-C4FB375D-DF6C-446D-85CC-3DCB1FF35653 Q33765938-CA8BDBED-E335-421D-9841-58090E463854 Q35069634-33BE8EC1-2CC6-4757-AAD5-66F7C1D8AE44 Q35532333-02C59120-5060-4AE6-9322-6DD81E727262 Q35617650-C40FDE46-84BC-4D44-817F-1B675BECEBFE Q36245820-21730F3D-5F41-493D-A645-07233F5A440B Q36246056-35E3D495-A878-4EC8-A21D-2936EF24A839 Q36438251-35DA034F-2E31-422B-9157-C6230288743B Q36516017-0FBB1569-5E00-45B6-9EF7-66693F5916BD Q36717766-2B2CD189-E6D1-4B86-8BFF-0C68B87A4FE6 Q36774814-7A32195A-D561-4A48-B9BA-72ACB0E3A7C9 Q37243371-53D191D1-E303-4820-B0B6-B410268EF5FA Q37618577-9295633F-A3E8-40C6-8B37-FFAA7B1528F0 Q37721695-5337C787-1950-4969-BAF7-6101A227F6BF Q38178271-92870D0E-DF8B-4EEE-BE2A-E90AD2CF5711 Q38596370-E31B69FD-43FB-4DAB-A785-41E685D76A98 Q38646384-E7FD79E6-4B58-4B9A-B30D-28DB5DAD9A07 Q38682042-48DF736D-8579-4C96-AC0D-52C4BF04580F Q38751905-012BB6BA-912B-413C-934A-9F47C136B9B8 Q39432157-30184D7F-3F2A-4E60-B0CB-39B4367C9441 Q41532980-FCC88ADC-0009-44DC-9392-A6362DF2B6AB Q42183970-FABB4793-13EB-4192-863E-EFDFCE16C92B Q42370114-7AB056EF-2F2A-4E79-A728-0933492C656D Q44475237-B4ADE747-C35D-45EA-8888-4F549208D16B Q47968875-8B2284C5-84A9-4DB9-B96D-B5AA9CB7F46B Q55129731-2CDF1869-F5A7-4374-904C-65B50D255B87 Q58051940-B161C76F-BAF3-4B3D-89EB-D4CDDE4CA235 Q59130718-51A1D308-F3AA-4129-85E8-AF88266AE5E2

P2860

Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases.

http://www.wikidata.org/entity/Q37412463

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases.

@en

Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases.

@nl

type

label

Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases.

@en

Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases.

@nl

prefLabel

Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases.

@en

Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases.

@nl

P1433

Q37412463-1B03FE69-A583-4020-857B-07EACFBCCC46

P1476

Q37412463-F43E81B2-1EE4-4ABB-B15C-F071579615DA

P2093

Q37412463-76299E1E-3B0A-4662-A5BD-32034F2A2525

Q37412463-B43741B9-232D-4648-B21B-E5FAF063EB4A

Q37412463-BCBDFB39-F386-4DBA-B178-0272141F002B

P2860

Q37412463-0DF8A1CD-F301-4AB6-9572-F89F8C9111FD

Q37412463-174FE25A-BE89-4DB3-A6A6-824B63A27AFA

Q37412463-1CF04AEF-2502-4AC6-A4B9-B6A704262C4E

Q37412463-22F11E96-53D2-4E17-B306-C4EBDBF0FE53

Q37412463-253FF632-AC6A-4646-A126-7A42A3E12366

Q37412463-273D4F27-B0CF-4EA8-AC08-5D59B1D93C69

Q37412463-2F471C2E-83DE-4195-9233-1971CE8844D5

Q37412463-34402C36-2E45-4CF1-AC35-2AD6D636A416

Q37412463-39341AB3-ACCA-4071-B68C-4C3696A5BD1E

Q37412463-41F9D1DB-03AC-4FCF-B058-FD02086DE217

P2888

Q37412463-B21B51C6-40F7-4341-8800-B3F3583388E3

P304

Q37412463-B851256C-6AE5-4E3B-A268-9662BDF1E159

P31

Q37412463-914DC1A1-31B9-4074-B175-CB41685345FB

P356

Q37412463-CCBF93F6-0980-448C-A940-957ECC8CAE10

Q37412463-E6740F49-804A-4ECB-BF56-A2EB0445572D

P433

Q37412463-4F2D6173-5DCE-4DEF-BEA7-AD062547F5D6

P478

Q37412463-2B02A0C2-905A-4695-B38F-F22D264ACD45

P50

Q37412463-1EE895A2-8CCD-434F-A594-8B0778FB6021

Q37412463-770C54BF-7F2C-44C7-A08D-CD9439DE8694

Q37412463-BDFE954B-BBAD-4DCB-BF57-A0E87DECCD84

P577

Q37412463-7EA18E56-3547-45D8-AFEF-EC426EAFE5FC

P698

Q37412463-9144BDA3-117A-470D-928F-7FFEC8E350BB

P921

Q37412463-2C493924-5C74-4986-AA83-D249BD4F7040

P932

Q37412463-AF31A55E-12D4-463F-9A22-F4DB9C62AA31

P356

S10165-009-0155-3

S10165-009-0155-3

P1433

Modern Rheumatology

P1476

Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases

@en

P2093

Edward K L Chan

http://www.w3.org/2001/XMLSchema#string

Minoru Satoh

http://www.w3.org/2001/XMLSchema#string

Monica Vázquez-Del Mercado

http://www.w3.org/2001/XMLSchema#string

P2860

A phosphorylated cytoplasmic autoantigen, GW182, associates with a unique population of human mRNAs within novel cytoplasmic speckles

Identification of an immunodominant epitope on RNA polymerase III recognized by systemic sclerosis sera: application to enzyme-linked immunosorbent assay

Disruption of GW bodies impairs mammalian RNA interference

The 1982 revised criteria for the classification of systemic lupus erythematosus

Antibodies to RNA polymerase III in systemic sclerosis detected by ELISA.

Autoantibody to NA14 is an independent marker primarily for Sjogren's syndrome

Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis

Range of antinuclear antibodies in "healthy" individuals.

Autoantibodies to RNA polymerase II are common in systemic lupus erythematosus and overlap syndrome. Specific recognition of the phosphorylated (IIO) form by a subset of human sera

Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD).

P2888

s10165-009-0155-3

P304

219-228

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10165-009-0155-3

http://www.w3.org/2001/XMLSchema#string

10.3109/S10165-009-0155-3

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Mónica Vázquez-Del Mercado

P577

2009-03-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19277826

http://www.w3.org/2001/XMLSchema#string

P921

P932

2876095

http://www.w3.org/2001/XMLSchema#string